Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ronald Weitzner

Rheumatology Sarasota, FL Medical Doctor

NPI 1942285937 CMS profile 269331

1945 Versailles St, 2Nd Floor, Sarasota, FL 34239

Open in the dashboard

General payments

$7,320

339 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$9,656 paid to institutions, not to them · program years 2019–2022

Through program year 2025, Ronald Weitzner of Sarasota, FL is reported in the CMS Open Payments database as having received $7,320 across 339 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $9,656 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 67th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $293 3
2024 General $562 5
2023 General $987 23
2022 General $1,023 58
2021 General $460 26
2020 General $1,490 81
2019 General $2,505 143

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ronald Weitzner
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Ronald Weitzner were reported at $293. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Ronald Weitzner Rheumatology median Middle half National median
2019 $2,505 $744 $153–$2,687 $163
2020 $1,490 $462 $98–$2,027 $114
2021 $460 $531 $101–$2,153 $132
2022 $1,023 $627 $125–$2,303 $149
2023 $987 $741 $145–$2,524 $160
2024 $562 $830 $166–$2,660 $164
2025 $293 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,105 48 payments
  2. Novartis Pharmaceuticals Corporation $852 58 payments
  3. Amgen Inc. $699 30 payments
  4. GlaxoSmithKline, LLC. $546 31 payments
  5. Pfizer Inc. $501 23 payments
  6. Janssen Biotech, Inc. $450 26 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $372 10 payments
  8. UCB, Inc. $369 15 payments
  9. Lilly USA, LLC $360 17 payments
  10. AstraZeneca Pharmaceuticals LP $330 7 payments
  11. Other $1,737 74 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,320 339 payments
Products named General payments · program years 2019–2025
  1. COSENTYX $689 53 payments
  2. RINVOQ $655 23 payments
  3. BENLYSTA $546 31 payments
  4. XELJANZ $450 19 payments
  5. SIMPONI ARIA $389 23 payments
  6. TALTZ $360 17 payments
  7. STELARA $344 19 payments
  8. TREMFYA $340 7 payments
  9. HUMIRA $337 18 payments
  10. KRYSTEXXA $306 18 payments
  11. Other $3,431 173 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

339 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record